NCT01082068 - Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions

Breast Cancer

Interventions

DRUG

XL147 (SAR245408)

given orally once daily as tablets

DRUG

XL765 (SAR245409)

given orally twice daily as capsules

DRUG

letrozole (Femara)

given orally once daily as tablets

Trial Locations (17)

27710

Investigational Site Number 1252, Durham

28041

Investigational Site Number 3413, Madrid

28050

Investigational Site Number 3420, Madrid

33901

Investigational Site Number 1238, Fort Meyers

37203

Investigational Site Number 1214, Nashville

44805

Investigational Site Number 3321, Nantes Saint Herblain

48109

Investigational Site Number 1331, Ann Arbor

48201

Investigational Site Number 1330, Detroit

60611

Investigational Site Number 1441, Chicago

65201

Investigational Site Number 5201, Columbia

75231

Investigational Site Number 3324, Paris

79915

Investigational Site Number 5246, El Paso

80262

Investigational Site Number 1601, Denver

90033

Investigational Site Number 1537, Los Angeles

02115

Investigational Site Number 1138, Boston

08035

Investigational Site Number 3415, Barcelona

08036

Investigational Site Number 3419, Barcelona